Sanofi and Regeneron Pharmaceuticals announced positive results from two Phase 3b/4 trials in patients with diabetes, finding that Praluent significantly reduced low-density lipoprotein cholesterol (LDL).
In the first study -- Odyssey DM-Insulin -- Praluent reduced LDL cholesterol by 48.2% compared with placebo in insulin-treated Type 2 diabetes patients with high cardiovascular risk and high levels of bad cholesterol not controlled by maximum tolerated doses (MTD) of statins.
The second study -- ODYSSEY DM-DYSLIPIDEMIA -- found that Praluent was superior to usual care in lowering non-HDL cholesterol.
The results were unveiled as part of the official symposium of the 77th Scientific Sessions of the American Diabetes Association in San Diego, CA
Read the press release
